Roche Xeloda Colorectal Use Clears FDA; Promotions Must Cite Camptosar
Executive Summary
Roche will study Xeloda in combination with Pharmacia's Camptosar in colorectal cancer patients following FDA approval of Xeloda April 30 for use in metastatic colorectal cancer patients.
You may also be interested in...
FDA Warns Roche On Xeloda Promotion; Agency Is Keeping Close Eye On Drug
FDA is directing Roche to conduct a broad corrective campaign for the chemotherapy agent Xeloda (capecitabine)
FDA Warns Roche On Xeloda Promotion; Agency Is Keeping Close Eye On Drug
FDA is directing Roche to conduct a broad corrective campaign for the chemotherapy agent Xeloda (capecitabine)
Roche Xeloda “Reminder” Ad Cited By FDA For Reference to Oral Delivery
Roche's use of the phrase "oral chemotherapy" in a direct-to-consumer "reminder" ad makes the ad product-specific for Xeloda, FDA said in a Jan. 9 letter